LC
FATE icon

Lindbrook Capital’s Fate Therapeutics FATE Stock Holding History

Lindbrook Capital’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-260
Closed -$910 – 2822
2024
Q3 		$910 Sell
260
-277
-52% -$1.08K ﹤0.01% 2521
2024
Q2 		$1.76K Sell
537
-252
-32% -$1.1K ﹤0.01% 2374
2024
Q1 		$5.79K Buy
789
+332
+73% +$2.06K ﹤0.01% 1835
2023
Q4 		$1.71K Buy
+457
New +$1.08K ﹤0.01% 2315
2023
Q2 		– Sell
-1,407
Closed -$8.02K – 2767
2023
Q1 		$8.02K Buy
1,407
+1,081
+332% +$6.52K ﹤0.01% 1594
2022
Q4 		$3.29K Buy
326
+119
+57% +$2.23K ﹤0.01% 2009
2022
Q3 		$5K Sell
207
-28
-12% -$809 ﹤0.01% 1662
2022
Q2 		$6K Buy
235
+45
+24% +$1.24K ﹤0.01% 1462
2022
Q1 		$7K Sell
190
-366
-66% -$14.2K ﹤0.01% 1441
2021
Q4 		$33K Buy
556
+520
+1,444% +$29.5K 0.01% 854
2021
Q3 		$2K Hold
36
– – ﹤0.01% 1527
2021
Q2 		$3K Sell
36
-33
-48% -$2.66K ﹤0.01% 1458
2021
Q1 		$6K Buy
69
+33
+92% +$3.16K ﹤0.01% 1205
2020
Q4 		$3K Buy
36
+24
+200% +$1.49K ﹤0.01% 1331
2020
Q3 		$0 Sell
12
-500
-98% -$17.5K ﹤0.01% 1776
2020
Q2 		$18K Buy
512
+469
+1,091% +$14K 0.01% 643
2020
Q1 		$1K Sell
43
-1,957
-98% -$49.5K ﹤0.01% 1442
2019
Q4 		$39K Buy
+2,000
New +$31.8K 0.01% 518

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Lindbrook Capital's FATE Position: Q4 2024 in Review

Lindbrook Capital sold out of Fate Therapeutics (FATE) in Q4 2024, closing a stake of 260 shares — an estimated $910 sold.

Lindbrook Capital first reported a position in FATE in Q4 2019 and held it in 18 quarters. The position peaked at $39K in Q4 2019. 159 funds tracked by Wall St. Rank hold FATE as of Q4 2024.

  • Lindbrook Capital reported no remaining Fate Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Lindbrook Capital sold 260 Fate Therapeutics shares in Q4 2024, an estimated $910.
  • Lindbrook Capital first reported a position in Fate Therapeutics in Q4 2019 and held it in 18 quarters.
  • Lindbrook Capital's Fate Therapeutics position peaked at $39K in Q4 2019.
  • 159 funds tracked by Wall St. Rank held Fate Therapeutics as of Q4 2024.

Based on Lindbrook Capital's 13F filing for Q4 2024, filed 6 Feb 2025.